AI in Clinical Trials: Acceleration, not Replacement

Catch the Full Episode

For this episode of The End Talks, Biorce CEO Pedro Coelho sits down with Pierre-Antoine André, a senior leader at IQVIA with more than 25 years of experience across consulting, pharma, and clinical trials.

They discuss how artificial intelligence is reshaping clinical development, how it is accelerating specific tasks and where the competitive advantage in pharma lies.

They explore:

• How AI is accelerating tasks like patient identification and protocol drafting

• Why CRO operations still depend on logistics, negotiation, and human relationships

• How can diversity be addressed in trials and why policies should be more stringent

• Why trust and human connection will remain essential in healthcare

AI will change how trials run. But trust remains the foundation of how the industry works.

They discuss how artificial intelligence is reshaping clinical development, how it is accelerating specific tasks and where the competitive advantage in pharma lies.

They explore:

• How AI is accelerating tasks like patient identification and protocol drafting

• Why CRO operations still depend on logistics, negotiation, and human relationships

• How can diversity be addressed in trials and why policies should be more stringent

• Why trust and human connection will remain essential in healthcare

AI will change how trials run. But trust remains the foundation of how the industry works.